Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Comment by XRRH2008on Jun 29, 2017 3:39pm
281 Views
Post# 26421158

RE:RE:Share consolidations are amateurish at best

RE:RE:Share consolidations are amateurish at bestWhy hire 2 PR firms a few months ago? Damned if I know. They had ZERO impact.

If they are expecting good results for the Phase1, why not wait until then to do the share conolidation. That would make more sense. Time it with something catalystic in nature. Their timing is off. Who planned this? Their janitor?

The consolidation will NOT get institutional interest. Sure, they can't play in penny stocks. That is correct. But they also have MINIMUM market cap restrictions, which the consolidation will do NOTHING to satisfy. So we will have less shares, most likely a smaller valuation, followed by another capital raise and still no institutional interest. Unless good Phase1 results are imminent, this stock is dead in the water and Alison is sinking fast. Time to throw her overboard.
<< Previous
Bullboard Posts
Next >>